Cyclo Therapeutics (CYTH) Insider Trading & Ownership $0.71 +0.03 (+4.42%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cyclo Therapeutics (NASDAQ:CYTH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.78%Number OfInsiders Buying(Last 3 Years)6Amount OfInsider Buying(Last 3 Years)$5.48 MNumber OfInsiders Selling(Last 3 Years)0 Get CYTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYTH Insider Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Cyclo Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/1/2023Rafael Holdings, Inc.Major ShareholderBuy4,000,000$1.25$5,000,000.00 4/20/2023Jeffrey TateCOOBuy29,941$0.71$21,258.11 4/20/2023Markus SiegerDirectorBuy59,881$0.71$42,515.51 4/20/2023N Scott FineCEOBuy299,402$0.71$212,575.42 9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00 9/21/2022Francis Patrick OstronicDirectorBuy5,000$1.76$8,800.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/20/2022Francis Patrick OstronicDirectorBuy5,000$2.04$10,200.00 5/16/2022Jeffrey TateCOOBuy3,000$2.12$6,360.00 4/28/2022Jeffrey TateCOOBuy635$2.50$1,587.50 3/29/2022Markus SiegerDirectorBuy10,000$2.73$27,300.00 2/7/2022N Scott FineCEOBuy10,334$3.58$36,995.72 1/24/2022Francis Patrick OstronicDirectorBuy2,000$3.75$7,500.00 1/19/2022Francis Patrick OstronicDirectorBuy1,132$4.00$4,528.00 1/19/2022N Scott FineCEOBuy5,000$3.89$19,450.00 1/14/2022Francis Patrick OstronicDirectorBuy2,137$4.00$8,548.00 12/15/2021Francis Patrick OstronicDirectorBuy3,000$3.90$11,700.00 12/15/2021N Scott FineCEOBuy5,000$3.89$19,450.00 12/3/2021Francis Patrick OstronicDirectorBuy864$4.75$4,104.00 12/2/2021Sharon Hemond HrynkowInsiderBuy1,000$4.98$4,980.00 12/1/2021Francis Patrick OstronicDirectorBuy5,000$5.00$25,000.00 (Data available from 1/1/2013 forward) CYTH Insider Trading Activity - Frequently Asked Questions Who is on Cyclo Therapeutics's Insider Roster? The list of insiders at Cyclo Therapeutics includes Francis Patrick Ostronic, Jeffrey Tate, Markus Sieger, N Scott Fine, Rafael Holdings, Inc., and Sharon Hemond Hrynkow. Learn more on insiders at CYTH. What percentage of Cyclo Therapeutics stock is owned by insiders? 29.78% of Cyclo Therapeutics stock is owned by insiders. Learn more on CYTH's insider holdings. Which Cyclo Therapeutics insiders have been buying company stock? The following insiders have purchased CYTH shares in the last 24 months: Jeffrey Tate ($21,258.11), Markus Sieger ($42,515.51), N Scott Fine ($212,575.42), and Rafael Holdings, Inc. ($5,000,000.00). How much insider buying is happening at Cyclo Therapeutics? Insiders have purchased a total of 4,389,224 CYTH shares in the last 24 months for a total of $5,276,349.04 bought. Cyclo Therapeutics Key ExecutivesMr. N. Scott Fine (Age 67)CEO & Director Compensation: $569.92kMr. C. E Strattan (Age 78)Founder & Director Mr. Joshua M. Fine (Age 42)CFO & Secretary Compensation: $421.17kMr. Michael Eric Lisjak (Age 50)Global Head of Regulatory Affairs & Senior VP of Business Development Compensation: $430.4kDr. Jeffrey L. Tate Ph.D. (Age 66)COO, Chief Quality Officer & Director Compensation: $255.14kMs. Lori McKennaGlobal Head of Patient AdvocacyDr. Karen Mullen FFPMInterim Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies QNCX Insider Selling CLSD Insider Selling CMRX Insider Selling FBLG Insider Selling AVTE Insider Selling EPIX Insider Selling PDSB Insider Selling VTGN Insider Selling ZIVO Insider Selling OVID Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:CYTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTH Stock Alerts